comparemela.com

Latest Breaking News On - Jula inrig - Page 5 : comparemela.com

Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)

Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Japan
Ryogoku
Chiba
Tokyo
United-kingdom
Naomi-eichenbaum
Nivi-nehra
Jula-inrig
Travere-therapeutics-inc
Exchange-commission
Nasdaq
International-symposium-on-iga-nephropathy

Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)

SAN DIEGO, Sept. 26, 2023 Travere Therapeutics, Inc. today announced that the Company and its collaborators will present preliminary findings from the SPARTAN Study evaluating the potential.

Japan
Tokyo
Ryogoku
Chiba
United-kingdom
Nivi-nehra
Jula-inrig
Naomi-eichenbaum
International-symposium-on-iga-nephropathy
Travere-therapeutics-inc
Nasdaq
Exchange-commission

Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023

Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Japan
United-kingdom
Milan
Lombardia
Italy
Germany
German
Jula-inrig
Naomi-eichenbaumvice
Nivi-nehravice
Nasdaq
Exchange-commission

Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023

08.06.2023 - SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) - Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present nine abstracts, including the interim analysis from the ongoing Phase 3 PROTECT Study . Seite 1

Milan
Lombardia
Italy
United-kingdom
Jula-inrig
Travere-therapeutics-inc
Nasdaq
United-kingdom-radar-registry

vimarsana © 2020. All Rights Reserved.